Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Dr Reddys unveils OTC...

    Dr Reddys unveils OTC store-brand equivalent of Prevacid 24HR Capsules in US to treat heartburn

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-09-17T13:06:37+05:30  |  Updated On 17 Sept 2019 1:06 PM IST
    Dr Reddys unveils OTC store-brand equivalent of Prevacid 24HR Capsules in US to treat heartburn

    Dr Reddy’s OTC Lansoprazole Delayed-Release Capsules USP, 15 mg, is an over-the-counter, Proton Pump Inhibitor (PPI) used to treat frequent heartburn occurring two or more days a week.


    Hyderabad: Dr Reddy’s Laboratories Ltd. (Dr Reddys )today announced the launch of Lansoprazole Delayed-Release Capsules USP, 15 mg, an over-the-counter (OTC) store-brand equivalent of Prevacid 24HR Capsules, in the United States market, as approved by the U.S. Food and Drug Administration (USFDA).


    Dr Reddy’s OTC Lansoprazole Delayed-Release Capsules USP, 15 mg, is an over-the-counter, Proton Pump Inhibitor (PPI) used to treat frequent heartburn occurring two or more days a week.


    Commenting on the same, Milan Kalawadia, Senior Vice President and Head of US OTC and Specialty Rx Divisions Dr Reddy’s Laboratories said, "We are pleased to continue to expand our antacids and PPI portfolio for our customers. We look forward to collaborating with our customers to provide high-quality, affordable alternatives to consumers.”


    The Prevacid 24HR brand and generic had U.S. sales of approximately $57 million MAT for the most recent twelve months ending in August 2019 according to IRI.


    Read Also: Dr Reddys gets EIR from USFDA for manufacturing plants at Duvvada


    Dr Reddy’s OTC Lansoprazole Delayed-Release Capsules USP, 15 mg, are available in 14, 28 and 42 count sizes.


    Prevacid is a registered trademark of Takeda Pharmaceuticals North America, Inc.



    Based in Hyderabad, Dr Reddys was founded by Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited, of Hyderabad, India.

    Read Also: Dr Reddys unveils a generic version of Zyban ER tablets in the US

    Dr Reddy'sDr Reddy's LaboratoriesDr Reddy's LabsDr reddys drugdr reddys otc drugdr reddys speciality divisionFood and Drug Administrationgeneric drugHeartburn drugLansoprazole Delayed Release Capsulespharmapharma companypharma newspharma news indiaPrevacidPrevacid 24HRTakeda PharmaUS marketUSFDAUSFDA approved

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok